KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $1.5 billion.

  • Alnylam Pharmaceuticals' Total Current Liabilities rose 2360.98% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 2360.98%. This contributed to the annual value of $1.5 billion for FY2025, which is 2360.98% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Total Current Liabilities stood at $1.5 billion, which was up 2360.98% from $1.6 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Total Current Liabilities high stood at $1.6 billion for Q3 2025, and its period low was $494.8 million during Q1 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Total Current Liabilities had a median value of $865.2 million in 2023 and averaged $917.1 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Total Current Liabilities soared by 4605.61% in 2021, and later surged by 1037.86% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Total Current Liabilities stood at $695.7 million in 2021, then increased by 10.38% to $767.9 million in 2022, then rose by 26.03% to $967.8 million in 2023, then grew by 22.58% to $1.2 billion in 2024, then increased by 23.61% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q4 2025, $1.6 billion for Q3 2025, and $1.3 billion during Q2 2025.